Dietary supplements are prescribed for products intended to supplement the diet, which may contain one or more of the following dietary ingredients, a vitamin, a mineral, an herb (herbal) or other plant, an amino acid, a food component used to increase the total daily intake to supplement the diet, or a concentrate, metabolite, component, extract or combination of the above ingredients. It also includes approved new drugs, vitamins or biologics that have been marketed as dietary supplements or food products before they are approved, issued or licensed. Small Molecule Peptides Powder:Bovine bone oligopeptide powder,Fish collagen peptide powder,Sunflower disk oligopeptide powder Dietary Supplements Ingredients,Dietary Ingredients,Dietary Supplement Ingredient,Nutrition Enhancers Shaanxi Zhongyi Kangjian Biotechnology Co.,Ltd , https://www.zhongyiherbs.com
Oat protein peptide powder,Corn oligopeptide powder,Soybean peptide powder,Whey protein peptide.
Amino acids include glycine, alanine, valine, leucine, isoleucine, methionine (methionine), proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine.
Breakthrough in early pathogenesis of heart failure
April 16, 2007
The early stages of heart failure pathogenesis have been significantly advanced. On April 2, 2007, after more than three years of dedicated research, a collaborative team led by Professor Zhang Youyi from the Institute of Vascular Medicine at Peking University Third Hospital and Professor Wang Shiqiang from the School of Life Sciences at Peking University made groundbreaking discoveries in understanding the molecular mechanisms behind early heart failure using animal models.
Their study focused on the calcium signaling process during cardiac excitation-contraction coupling, examining it at both cellular and subcellular levels. They also investigated dihydropyridine receptors (DHPR) and Ryanodine receptors (RyR) from an intermolecular interaction perspective. For the first time, they demonstrated that the coupling efficiency between DHPR and RyR decreases during the early stages of cardiac hypertrophy, even before any noticeable changes in contractile function occur. This decline was attributed to reduced expression of junctophilin, an anchoring protein that determines the spatial arrangement of these two molecules. This change leads to impaired calcium transients and, ultimately, reduced contractility.
This finding highlights key molecular-level changes that occur in the early stages of heart failure. Based on their results, the researchers introduced the concept of a "stability margin" in physiological functions. Using experimental data and mathematical models, they showed that this stability margin is essential for maintaining functional stability in systems like cellular calcium signaling. When this margin is depleted, the progressive loss of molecular coupling efficiency manifests as worsening calcium signaling and contractile dysfunction.
This theoretical framework provides valuable insights into the progression of heart failure and lays the foundation for earlier diagnosis and prevention strategies. The study represents a significant step forward in understanding the complex mechanisms underlying heart failure at the molecular level. — Midi Medical Network